FOR PATIENTS WITH POMPE DISEASE

KEEP ACTIVE POSSIBLE

Initiating MYOZYME® upon diagnosis of Pompe disease increases acid α-glucosidase (GAA) activity—to stabilize respiratory function and improve and maintain mobility so patients can stay active and preserve their quality of life[1]

All photos are actor portrayals, not actual patients.

Pompe disease calls for an immediate response: treat with MYOZYME.[2,3]

MYOZYME is indicated for long-term enzyme replacement therapy (ERT) in adults and pediatric patients of all ages with a confirmed diagnosis of Pompe disease (acid α-glucosidase deficiency).[1]

Myozyme®
(alglucosidase alfa)

MYOZYME®: approved long-term treatment for Pompe disease that addresses the underlying cause to keep patients going[1]

In adult patients with LOPD, MYOZYME:

- **Helped to retain breathing function,** stabilizing pulmonary function and preserving ventilatory status in most patients[20,25]
- **Maintained independent walking,** sustaining long-term mobility in adult patients with LOPD[20]

In pediatric patients with LOPD, MYOZYME:

- **Improved respiratory health,** stabilizing or improving pulmonary function, and reducing the need for ventilatory support[24,27]
- **Enabled continued participation in activities of daily living,** increasing or stabilizing motor function, allowing patients to maintain mobility[22,24,26,27]

In patients with IOPD, MYOZYME:

- **Increased survival and achievement of motor function milestones,** prolonging life, increasing ventilator-free survival, and stabilizing cardiac health and motor function[1,15,29-31]

Please review Product Information before prescribing.
Please Scan the QR code to access Full SMPC.

SANOFI GENZYME

Myozyme® (alglucosidase alfa)

SANOFI, Level 3, One JLT, Jumeirah Lake Towers (JLT), DMCC, PO Box 53899, Dubai, UAE |
Tel.: +971 4 550 3600 | Fax: +971 4 5521050
For further medical information, Please contact: For UAE 800 MEDICAL Toll Free Number,
For all Gulf Countries +971 565776791 or email: medical-information.gulf@sanofi.com
To report an adverse events please call: +971 561747001 or email:
Gulf.Pharmacovigilance@sanofi.com
https://www.sanofi.com

MAT-AE-2100623 - V1 - October 2021